SEC filing record
Primary Source · SEC.gov

Paragon Biosciences Emalex Capital, Inc.

2022 vintageRule 506(b)Filing record

Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form D; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.

Latest signalSold increasedForm D/A · 2025-07-086 events: 2 sold increased, 2 large raise, 1 offering upsizedLast filing 2025-07-08

Raised

$270M

Investors

42

Min Invest

$1,072

AltStreet Verified Issuer badge

Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.

What this filing shows

·

Every sentence is a value as filed on SEC Form D

Paragon Biosciences Emalex Capital, Inc. is a Delaware corporation that first filed a Form D on August 14, 2018 and most recently amended it on July 8, 2025 in the Pharmaceuticals industry group. The offering claims Rule 506(b) and covers equity. Paragon Biosciences Emalex Capital, Inc. reported $270,000,000 sold from 42 investors of a $270,000,000 total offering as of the Form D filed July 8, 2025. The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The minimum investment accepted from an outside investor is $1,072. The Form D names Paragon Health Capital, LLC (CRD 300729), associated with None as the recipient of sales compensation soliciting in CT, FL, IL, MA, NJ, NY, PA. Sales commissions are reported as $5,669,958 and finders' fees as $0. Form D allows these to be estimates. The issuer's address of record is 303 N Wabash Ave, Suite # 3500, Chicaco, IL 60611.

EDGAR Filing Data

Form D — Primary Source

View on SEC.gov
CIK Number0001749990
Entity NameParagon Biosciences Emalex Capital, Inc.
ExemptionRule 506(b)
What the exemption meansRule 506(b) of Regulation D: securities may be sold to an unlimited number of accredited investors and up to 35 non-accredited investors who meet the rule's sophistication standard, without general solicitation or advertising.
Entity TypeCorporation
Jurisdiction of OrganizationDelaware
Issuer Address303 N Wabash Ave, Suite # 3500, Chicaco, IL 60611
Phone(847) 715-0606
Industry / Fund TypePharmaceuticals
Securities TypeEquity
First Sale DateMay 18, 2022
Filing DateJuly 8, 2025
Accession Number0001749990-25-000003
Total Offering Amount$270,000,000
Total Amount Sold$270,000,000
Amount Remaining$0
Total Investors42
Non-Accredited InvestorsNone
Minimum Investment$1,072
Offering DurationIntended to last more than one year
Sales Commissions$5,669,958 (to Paragon Health Capital, LLC)
Finders' Fees$0
Revenue RangeDecline to Disclose
State (Issuer Address)IL
Amendment Count10 filings on record

Filings on Record

Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.

In the Terminal

Filing events

6

latest Jul 8, 2025

Critical / warning

0 / 1

5 watch · 0 info

Statements extracted

0

none on file

NAV prints

0

none on file

Offering chains

5

closed

Latest event Sold increase · Jul 8, 2025

SEC.gov
Open in the terminal Watch this issuerInvestor $149/mo unlocks the values; Pro $349/mo adds the universe.

Investor

  • 6 filing events with values and deltas, latest 2025-07-08, and alerts on the next one
  • 5 offering timelines: velocity, share raised, first-sale lag, stalled flags

Pro

  • This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
  • The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV

Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…

Related Persons (Form D)

Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.

Item 3 changed on the Form D filed 2025-07-08: 0 related persons added and 1 removed against the filing of 2025-03-25; 7 now listed. The names are in the Terminal feed.

Patrick J. Morris

Executive Officer · Chicago, IL

Jeffrey J. Aronin

Director · Chicago, IL

Antonio J. Gracias

Director · Chicago, IL

Darien J. Parhad

Executive Officer · Chicago, IL

Eric J. Messner

Executive Officer, Director · Chicago, IL

Jeffrey J. Dayno

Director · Chicago, IL

Ricky J. Sun

Director · Chicago, IL

Placement Agents and Sales Compensation (Form D)

Who the issuer reported paying to sell the securities (Form D Item 12), with the FINRA registration number the filer gave. Source: SEC.gov.

Paragon Health Capital, LLCCRD 300729 on BrokerCheck

Associated broker-dealer: None · Chicago, IL · Soliciting in CT, FL, IL, MA, NJ, NY, PA

Questions About Paragon Biosciences Emalex Capital, Inc.

Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.

What is Paragon Biosciences Emalex Capital, Inc.?

Paragon Biosciences Emalex Capital, Inc. is a Delaware corporation that filed a Form D with the SEC on July 8, 2025 in the Pharmaceuticals industry group. The filing claims Rule 506(b) for an offering of equity.

Is Paragon Biosciences Emalex Capital, Inc. legit?

AltStreet does not rate legitimacy; it reports the public record. Paragon Biosciences Emalex Capital, Inc. filed a Form D with the SEC on July 8, 2025 claiming Rule 506(b). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $270,000,000 sold to 42 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.

Is Paragon Biosciences Emalex Capital, Inc. registered with or approved by the SEC?

No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Paragon Biosciences Emalex Capital, Inc. claimed Rule 506(b) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.

How much has Paragon Biosciences Emalex Capital, Inc. raised?

Paragon Biosciences Emalex Capital, Inc. reported $270,000,000 sold from 42 investors of a $270,000,000 total offering as of the Form D filed July 8, 2025.

Who can invest in Paragon Biosciences Emalex Capital, Inc.?

The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The minimum investment accepted from an outside investor is $1,072.

What is the minimum investment in Paragon Biosciences Emalex Capital, Inc.?

The Form D lists $1,072 as the minimum investment accepted from any outside investor as of July 8, 2025. Issuers can waive their own minimums, and the figure does not include fees.

Who is selling Paragon Biosciences Emalex Capital, Inc. and how are they paid?

The Form D names Paragon Health Capital, LLC (CRD 300729), associated with None as the recipient of sales compensation soliciting in CT, FL, IL, MA, NJ, NY, PA. Sales commissions are reported as $5,669,958 and finders' fees as $0. Form D allows these to be estimates.

Who is behind Paragon Biosciences Emalex Capital, Inc.?

The Form D lists 7 related persons: Patrick J. Morris, executive officer; Jeffrey J. Aronin, director; Antonio J. Gracias, director; Darien J. Parhad, executive officer; Eric J. Messner, executive officer, director; Jeffrey J. Dayno, director; Ricky J. Sun, director. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.

Where is Paragon Biosciences Emalex Capital, Inc. located?

The issuer's address on its SEC filings is 303 N Wabash Ave, Suite # 3500, Chicaco, IL 60611. Its phone number of record is (847) 715-0606. It is organized under the laws of Delaware.

How long is the Paragon Biosciences Emalex Capital, Inc. offering open?

The issuer indicated that the offering is intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open; 5 amendments are on record for this CIK.

What is Paragon Biosciences Emalex Capital, Inc.'s revenue?

The issuer declined to disclose its revenue range on the Form D, which the form permits.

AltStreet Verified Issuer badge

Is this your company or fund?

Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.

Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.

Data Methodology

Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.